Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Germany
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Minjuvi (tafasitamab) is a CD19-directed monoclonal antibody that targets and depletes CD19-expressing B-cells, used in combination with lenalidomide for certain B-cell lymphomas. Minjuvi is the brand name used in Europe and other international markets; the same active ingredient is marketed in the United States as Monjuvi.
Minjuvi, in combination with lenalidomide, is approved for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant.
Tafasitamab binds to CD19 on the surface of B-cells and mediates cell lysis through antibody-dependent cellular cytotoxicity and phagocytosis, working synergistically with lenalidomide's immunomodulatory effects.
The recommended dose is 12 mg/kg administered as an intravenous infusion in 28-day cycles, combined with lenalidomide for up to 12 cycles, followed by Minjuvi monotherapy, as determined by the treating hematologist-oncologist.
Minjuvi requires close monitoring for several serious adverse effects, particularly during the initial infusion cycles.
Can occur, particularly during the first infusion. Monitor closely and manage with infusion interruption or premedication as needed.
Neutropenia, thrombocytopenia, and anemia are common. Monitor complete blood counts regularly, especially during the first cycles.
Serious infections, including opportunistic infections, have been reported. Monitor for signs of infection throughout treatment.
Minjuvi combined with lenalidomide can cause fetal harm. Effective contraception is required during treatment and for a defined period after the final dose. Lenalidomide itself carries additional pregnancy-related restrictions.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Minjuvi (tafasitamab) is marketed by Incyte Corporation, which holds exclusive global rights to tafasitamab. Minjuvi is the brand name used in Europe, Japan, and other international markets; the same active ingredient is marketed in the United States as Monjuvi.
Import of Minjuvi through a Named Patient Program requires a valid prescription from the treating hematologist-oncologist, confirmation of DLBCL diagnosis and transplant-eligibility status, and supporting clinical documentation as required by Indian regulatory authorities.
NPP sources Minjuvi directly from Incyte's authorized supply chain to ensure product authenticity and regulatory compliance.
Minjuvi is sourced through verified, GDP-compliant, cold-chain channels from Incyte's authorized supply chain to ensure authenticity and quality.
Minjuvi should be stored refrigerated at 2°C to 8°C. Do not freeze.
Once sourced, Minjuvi is packed and transported under continuous cold-chain conditions to preserve product integrity throughout the import process, with tracking and updates provided at each stage of delivery to the patient or treating hospital in India.
Patients across India can access Minjuvi through NPP's regulated import pathway, with hematology-oncology specialists in major cities supporting the treatment process.
Leading hematology-oncology centers in Mumbai support DLBCL diagnosis and treatment coordination for Minjuvi access.
Delhi's major cancer hospitals assist patients with diagnostic confirmation and prescription support for Minjuvi.
Bangalore's oncology network offers access to lymphoma treatment planning for eligible DLBCL patients.
Chennai-based specialists coordinate Minjuvi access alongside comprehensive lymphoma care.
Hyderabad's cancer care institutions support patients pursuing Minjuvi therapy.
Kolkata's oncology centers help coordinate documentation and treatment access for Minjuvi.
Pune-based hematologists assist with diagnosis confirmation and Minjuvi treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Minjuvi.
Kochi's oncology units assist patients with the documentation needed for Minjuvi access.
Chandigarh's cancer care centers support Minjuvi treatment coordination for patients from North India.
Jaipur's oncology specialists help patients navigate the Minjuvi access process.
Lucknow-based cancer centers assist patients pursuing Minjuvi therapy.
Bhubaneswar's oncology institutions support access to Minjuvi for eligible patients.
Guwahati's specialists help coordinate Minjuvi access for patients across the Northeast.
Patients in other cities across India can also access Minjuvi through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 09 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 09 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
